<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="52007">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01981330</url>
  </required_header>
  <id_info>
    <org_study_id>2010/1650</org_study_id>
    <nct_id>NCT01981330</nct_id>
  </id_info>
  <brief_title>Pilot Study of Stem Cell Treatment of Patients With Vocal Fold Scarring</brief_title>
  <official_title>Pilot Study of 8 Patients With Severe Hoarseness and Vocal Fold Scarring Treated With Mesenchymal Stem Cells With and Without Hyaluronan Gel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Swedish Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laryngfonden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <authority>Sweden: Regional Ethical Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot-study of 8 selected Swedish patients which all have severe hoarseness or
      aphonia due to vocal fold scarring  (from previous surgery, radiation therapy, inflammation
      or possibly hereditary). The patients are operated with phonomicrosurgical dissection of the
      scarred vocal folds, removal or scar tissue and injection of autologous mesenchymal stem
      cells, aMSC (which were previously harvested from each patients´s bone marrow, purified,
      expanded and characterized according to standard procedure at the Center of Hematology and
      Regenerative Medicine Karolinska University Hospital Huddinge). 5 Patients will be treated
      with a single injection of aMSC and 3 patients with injection of aMSC mixed with a carrier
      hyaluronan gel developed at Uppsala University Sweden and at the Karolinska Institute. The
      laryngeal status, vocal fold function, and voice function will be followed individually with
      an advanced battery of examinations performed before and up to 1 year postoperatively. Blood
      samples for e.g. inflammatory parameters, will be obtained before and up to 24-48 hours
      postoperatively
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Improved healing of scarred vocal folds</measure>
    <time_frame>1 year postoperatively</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Laryngeal and general ear, nose, and throat status will be followed for each patient at least one year after primary treatment. This includes examination of signs of local (laryngeal) inflammatory reaction/defect healing, e.g. polyp or granuloma formation as well as blood samples for immediate (up to 48h), inflammatory reaction after local aMSC injection It also includes repetitive examinations of vocal fold function and voice function including high speed examination of the vocal folds, acoustic voice analysis and phonation pressure measurements as well as subjective ratings by means of Voice handicap index scale</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Improved Healing of Scarred Vocal Folds</condition>
  <condition>Improved Vocal Fold Status</condition>
  <condition>Improved Vocal Fold Function</condition>
  <arm_group>
    <arm_group_label>aMSC with and without hyaluronan gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>autologous mesenchymal stem cells (aMSC) injected into the vocal folds in 5 patients and aM&gt;SC mixed with hyaluronan gel in 3 patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aMSC</intervention_name>
    <description>aMSC injected into the vocal fold of the patient</description>
    <arm_group_label>aMSC with and without hyaluronan gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aMSC+hyaluronan gel</intervention_name>
    <description>aMSC+ hyaluronan gel is injected into the patients vocal fold</description>
    <arm_group_label>aMSC with and without hyaluronan gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  severe hoarseness

          -  vocal fold scarring

          -  no active other treatment

          -  age above 18 years

        Exclusion Criteria:

          -  active treatment of laryngeal disorder

          -  active inflammatory condition of the larynx

          -  diagnosed or suspicions of local malignancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stellan Hertegård, MD, PhD</last_name>
      <phone>+46707561295</phone>
      <email>Stellan.Hertegard@ki.se</email>
    </contact>
    <contact_backup>
      <last_name>Katarina LeBlanc, Professor</last_name>
      <phone>+46858580000</phone>
      <email>Katarina.Leblanc@ki.se</email>
    </contact_backup>
    <investigator>
      <last_name>Stellan Hertegård, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katarina LeBlanc, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 8, 2013</lastchanged_date>
  <firstreceived_date>November 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Stellan Hertegård</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>vocal fold scarring</keyword>
  <keyword>mesenchymal stem cells</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cicatrix</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
